WAM
ERNA icon

Warberg Asset Management’s Eterna Therapeutics ERNA Stock Holding History

Warberg Asset Management’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,000
Closed -$10.1K – 179
2026
Q1 		$10.1K Buy
+2,000
New +$31.9K ﹤0.01% 167

Other funds holding ERNA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Warberg Asset Management's ERNA Position: Q2 2026 in Review

Warberg Asset Management sold out of Eterna Therapeutics (ERNA) in Q2 2026, closing a stake of 2,000 shares — an estimated $10.1K sold.

Warberg Asset Management first reported a position in ERNA in Q1 2026 and held it in 1 quarter. The position peaked at $10.1K in Q1 2026. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • Warberg Asset Management reported no remaining Eterna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Warberg Asset Management sold 2,000 Eterna Therapeutics shares in Q2 2026, an estimated $10.1K.
  • Warberg Asset Management first reported a position in Eterna Therapeutics in Q1 2026 and held it in 1 quarter.
  • Warberg Asset Management's Eterna Therapeutics position peaked at $10.1K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on Warberg Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.